Literature DB >> 23347175

SMAD regulatory networks construct a balanced immune system.

Nidhi Malhotra1, Joonsoo Kang.   

Abstract

A balanced immune response requires combating infectious assaults while striving to maintain quiescence towards the self. One of the central players in this process is the pleiotropic cytokine transforming growth factor-β (TGF-β), whose deficiency results in spontaneous systemic autoimmunity in mice. The dominant function of TGF-β is to regulate the peripheral immune homeostasis, particularly in the microbe-rich and antigen-rich environment of the gut. To maintain intestinal integrity, the epithelial cells, myeloid cells and lymphocytes that inhabit the gut secrete TGF-β, which acts in both paracrine and autocrine fashions to activate its signal transducers, the SMAD transcription factors. The SMAD pathway regulates the production of IgA by B cells, maintains the protective mucosal barrier and promotes the balanced differentiation of CD4(+) T cells into inflammatory T helper type 17 cells and suppressive FOXP3(+) T regulatory cells. While encounters with pathogenic microbes activate SMAD proteins to evoke a protective inflammatory immune response, SMAD activation and synergism with immunoregulatory factors such as the vitamin A metabolite retinoic acid enforce immunosuppression toward commensal microbes and innocuous food antigens. Such complementary context-dependent functions of TGF-β are achieved by the co-operation of SMAD proteins with distinct dominant transcription activators and accessory chromatin modifiers. This review highlights recent advances in unravelling the molecular basis for the multi-faceted functions of TGF-β in the gut that are dictacted by fluid orchestrations of SMADs and their myriad partners.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347175      PMCID: PMC3634534          DOI: 10.1111/imm.12076

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  141 in total

1.  The surprising discovery that TGF beta specifically induces the IgA class switch.

Authors:  Janet Stavnezer; Joonsoo Kang
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 2.  Regulatory T cells and immune tolerance.

Authors:  Shimon Sakaguchi; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono
Journal:  Cell       Date:  2008-05-30       Impact factor: 41.582

Review 3.  The immune geography of IgA induction and function.

Authors:  A J Macpherson; K D McCoy; F-E Johansen; P Brandtzaeg
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

4.  Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.

Authors:  Xuexian O Yang; Roza Nurieva; Gustavo J Martinez; Hong Soon Kang; Yeonseok Chung; Bhanu P Pappu; Bhavin Shah; Seon Hee Chang; Kimberly S Schluns; Stephanie S Watowich; Xin-Hua Feng; Anton M Jetten; Chen Dong
Journal:  Immunity       Date:  2008-06-26       Impact factor: 31.745

5.  Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression.

Authors:  Sheng Xiao; Hulin Jin; Thomas Korn; Sue M Liu; Mohamed Oukka; Bing Lim; Vijay K Kuchroo
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

6.  Late developmental plasticity in the T helper 17 lineage.

Authors:  Yun Kyung Lee; Henrietta Turner; Craig L Maynard; James R Oliver; Dongquan Chen; Charles O Elson; Casey T Weaver
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

7.  The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.

Authors:  Alessandro Sorrentino; Noopur Thakur; Susanne Grimsby; Anders Marcusson; Verena von Bulow; Norbert Schuster; Shouting Zhang; Carl-Henrik Heldin; Maréne Landström
Journal:  Nat Cell Biol       Date:  2008-08-31       Impact factor: 28.824

8.  Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.

Authors:  Jeremy B Samon; Ameya Champhekar; Lisa M Minter; Janice C Telfer; Lucio Miele; Abdul Fauq; Pritam Das; Todd E Golde; Barbara A Osborne
Journal:  Blood       Date:  2008-06-11       Impact factor: 22.113

Review 9.  TGF-beta: a master of all T cell trades.

Authors:  Ming O Li; Richard A Flavell
Journal:  Cell       Date:  2008-08-08       Impact factor: 41.582

10.  IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.

Authors:  Valérie Dardalhon; Amit Awasthi; Hyoung Kwon; George Galileos; Wenda Gao; Raymond A Sobel; Meike Mitsdoerffer; Terry B Strom; Wassim Elyaman; I-Cheng Ho; Samia Khoury; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

View more
  35 in total

1.  TGF-β1 Suppresses IL-33-Induced Mast Cell Function.

Authors:  Victor S Ndaw; Daniel Abebayehu; Andrew J Spence; Patrick A Paez; E Motunrayo Kolawole; Marcela T Taruselli; Heather L Caslin; Alena P Chumanevich; Anuya Paranjape; Bianca Baker; Brian O Barnstein; Tamara T Haque; Kasalina N Kiwanuka; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

Review 2.  Nematodes and human therapeutic trials for inflammatory disease.

Authors:  D E Elliott; J V Weinstock
Journal:  Parasite Immunol       Date:  2017-04-18       Impact factor: 2.280

Review 3.  Development and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signals.

Authors:  Joseph H Chewning; Casey T Weaver
Journal:  J Immunol       Date:  2014-11-15       Impact factor: 5.422

4.  Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts.

Authors:  A Paradowska-Gorycka; K Romanowska-Próchnicka; E Haladyj; M Manczak; S Maslinski; M Olesinska
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

5.  Interleukin-10 Modulation of Virus Clearance and Disease in Mice with Alphaviral Encephalomyelitis.

Authors:  Nina M Martin; Diane E Griffin
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

6.  RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis.

Authors:  Violeta Rus; Vinh Nguyen; Alexandru Tatomir; Jason R Lees; Armugam P Mekala; Dallas Boodhoo; Cosmin A Tegla; Irina G Luzina; Paul A Antony; Cornelia D Cudrici; Tudor C Badea; Horea G Rus
Journal:  J Immunol       Date:  2017-03-29       Impact factor: 5.422

7.  Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium.

Authors:  Chi-Chen Hong; Lara E Sucheston-Campbell; Song Liu; Qiang Hu; Song Yao; Kathryn L Lunetta; Stephen A Haddad; Edward A Ruiz-Narváez; Jeannette T Bensen; Ting-Yuan David Cheng; Elisa V Bandera; Lynn A Rosenberg; Christopher A Haiman; Kelvin Lee; Sharon S Evans; Scott I Abrams; Elizabeth A Repasky; Andrew F Olshan; Julie R Palmer; Christine B Ambrosone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01-16       Impact factor: 4.254

8.  Aryl hydrocarbon receptor-induced activation of the human IGH hs1.2 enhancer: Mutational analysis of putative regulatory binding motifs.

Authors:  Andrew D Snyder; Sharon D Ochs; Brooke E Johnson; Courtney E W Sulentic
Journal:  Mol Immunol       Date:  2020-03-06       Impact factor: 4.407

9.  Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis.

Authors:  Steffen Haupeltshofer; Teresa Leichsenring; Sarah Berg; Xiomara Pedreiturria; Stephanie C Joachim; Iris Tischoff; Jan-Michel Otte; Tobias Bopp; Massimo C Fantini; Charlotte Esser; Dieter Willbold; Ralf Gold; Simon Faissner; Ingo Kleiter
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-03       Impact factor: 11.205

10.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Authors:  Zijun Y Xu-Monette; Bouthaina S Dabaja; Xiaoxiao Wang; Meifeng Tu; Ganiraju C Manyam; Alexander Tzankov; Yi Xia; Li Zhang; Ruifang Sun; Carlo Visco; Karen Dybkaer; Lihui Yin; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Xiaoying Zhao; Jane N Winter; Miguel A Piris; Timothy J McDonnell; Roberto N Miranda; Yong Li; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2015-11-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.